• Aims and scope
• Transparent Editorial Process
• Bibliometrics
• Charges & Open Access
• Privacy Policy

AIMS AND SCOPE

EMBO Molecular Medicine is an open access journal in the field of experimental medicine, dedicated to science at the interface between clinical research and basic life sciences. In addition to human data, we welcome original studies performed in cells and/or animals provided they demonstrate human disease relevance.

To enhance and better specify our commitment to precision medicine, we have expanded the scope of EMM and call for contributions in the following fields:

1. Environmental health and medicine, in particular studies in the field of environmental medicine in its functional and mechanistic aspects (exposome studies, toxicology, biomarkers, modeling, and intervention).
2. Clinical studies and case reports - Human clinical studies providing decisive clues how to control a given disease (epidemiological, pathophysiological, therapeutic, and vaccine studies). Case reports supporting hypothesis-driven research on the disease.
3. Biomedical technologies - Studies that present innovative materials, tools, devices, and technologies with direct translational potential and applicability (imaging technologies, drug delivery systems, tissue engineering, and AI)

The journal is one of four EMBO Press journals run by in-house professional scientific editors. EMBO Molecular Medicine is supported by our academic Chief Editor, Prof. Philippe Sansonetti, and our broad and diverse advisory editorial board. Our journal is editorially independent of its publisher Springer Nature. For further details on our relationship to other EMBO Press publications, please see below.

EMBO Molecular Medicine publishes research papers as full-length Articles, short Reports, Methods and Resource articles. In addition, the journal publishes Editorials and Reviews in innovative formats that target a broad and non-specialized audience, as well as News & Views, Opinions and Comments.

Areas covered include, but are not limited to:

• Vascular and cardiovascular biology
• Infectious diseases and vaccines
• Microbiome
• Endocrinology and metabolic diseases
• Stem cells and regenerative medicine
• Systems medicine and clinical genomics
• Aging
• Neurodegeneration and neurological diseases 
• Myopathies and musculoskeletal disease
• Gene and cell therapy
• Human genetics, autoimmunity, and rare diseases
• Immunology and inflammation
• Oncology
• Molecular diagnostics, biomarkers and imaging
• Drug discovery
• Mitochondrial diseases
• Gastroenterology
• Nephrology
• Respiratory diseases
• Reproductive medicine
• Biomedical technologies
• Human clinical studies
• Case reports
• Exposome studies
• Toxicology

Citing EMBO Molecular Medicine Articles

EMBO Molecular Medicine articles are cited according to their full article identifier as follows:

Morais VA, Verstreken P, Roethig A, Smet J, Snellinx A, Vanbrabant M, Haddad D, Frezza C, Mandemakers W, Vogt-Weisenhorn D, Van Coster R, Wurst W, Scorrano L, De Strooper B (2009) Parkinson's disease mutations in PINK1 result in decreased complex I activity and deficient synaptic function. EMBO Mol Med 1: 99-111

TRANSPARENT EDITORIAL PROCESS

EMBO Molecular Medicine has a fair and transparent process to rapidly publish important science.

Transparent Review

• No confidential referee remarks
• Published anonymous referee reports and editorial correspondence
• Editors respect requests to exclude specific referees
• Editors justify editorial decisions in detail and specify what is required for a revision

Flexible Formatting

• No journal-specific formatting required at submission; manuscripts are assessed for science, not for style

Scooping Protection

• Similar findings that are published by others during review or revision are not a criterion for rejection
• In exceptional circumstances, editors may consider manuscripts that have just been scooped

Cross-Referee Commenting

• Referees are invited to comment on each other's reports before the editor makes a decision, ensuring a balanced review process

Single Round

• Papers rarely undergo more than one major round of revision
• Referees are asked to focus on essential revisions and to consider the feasibility of experiments they suggest
• Revisions are invited only if they are possible in a realistic time frame
• Editors ensure that referees do not raise new non-essential points upon revision
• More than 90% of invited revisions are published at EMBO Molecular Medicine

Fast Process

• Editorial decisions are returned within a week and referee comments in less than a month
• After acceptance, we can publish fully edited papers within 10 days

Approachable Editors

• Authors can discuss manuscripts with editors at any stage in the process, including during revision and following rejection. Editors may invite author feedback on referee reports before reaching a decision

Informed Evaluation

• Scientific editors undertake a comprehensive evaluation of each manuscript. Editorial board members advise rapidly on manuscripts

Source Data

• Authors are encouraged to publish the unprocessed source data underlying graphs, gels and micrographs alongside the figures to promote data transparency and reuse
• Supplementary information is restricted to essential data supporting key claims in the main paper. Structured datasets, models and detailed protocols are also permitted

Manuscript Transfers

• Authors can elect to transfer manuscripts with referee reports between the EMBO publications. Editors prioritize transfers and base decisions on the available information, ensuring exceptional manuscripts can be published without delay

EDITORIAL TURNTIMES* & BIBLIOMETRICS - 2023

*Median number of days from submission

EMBO Molecular Medicine encourages applying due care in interpreting bibliometric measures such as CiteScore, h5-Index and Journal Impact Factor among others. EMBO Press is a foundation signatory of the San Francisco Declaration on Research Assessment (DORA) pointing to flaws in the Journal Impact Factor, particularly in its application to the assessment of the research output of individuals. Please read this editorial for a more detailed discussion [The EMBO Journal (2015) 34, 1601-1602].

Citation Distribution of Items Cited in 2021

Journal Citation Reports (Clarivate Analytics, 2022)

CHARGES & OPEN ACCESS

All papers are published Open Access (OA) under a Creative Commons CC-BY 4.0 license. OA publishing is supported by article processing charges (APCs), payable by authors, their institutions, or funders when articles are accepted for publication.

• The list APC for Research Articles, Reports, Resource, Methods and Reviews is: €6490/$6890/£5590*
• The list APC for a Comment is: €2000/$2090/£1690*

*APCs are subject to VAT or local taxes where applicable. Charges for Reviews or Comments only apply to non-commissioned articles or where institutional publishing support covers the costs. No additional charges apply, and all other article types are exempt from charges.

Tiered APC Pricing: EMBO Molecular Medicine is part of Springer Nature’s country-tiered APC pricing pilot, which allocates countries to a pricing tier (a percentage of the journal’s standard APC, ranging from 100% to 0%) created using information from a number of sources, including real-world availability of funding in any given country, as well as their historic waiver and discount needs. The APC is set automatically upon an article’s acceptance, based on the corresponding author’s country of residence. Find out more about the APC applicable to your country.

Open Access Funding: Information about research funders and institutions that provide funding for APCs can be found here: open access funding & support services. You can also check your eligibility under Springer Nature’s institutional open access agreements and discover whether this journal is included.

Waivers and Discounts: In cases where the country-tiered APC cannot be funded through an OA agreement, institutional, funder or other APC support, and where insufficient funds for the applicable APC are available, requests for APC waivers and discounts can be made. Such requests from authors will be considered on a case-by-case basis, and will only be granted in cases of financial need (see Springer Nature’s open access policies for journals for more information). All applications for discretionary APC waivers and discounts should be made at the point of manuscript submission; requests made during the review process or after acceptance are unable to be considered.

EMBO Programme Support for APCs: EMBO Press will ensure that no author is excluded from its journals due to a documented inability to pay for publication charges and so offers further APC support programmes for authors in the following categories:

• Corresponding authors of articles accepted in 2024 based in Croatia, Czech Republic, Estonia, Greece, Hungary, Italy, Lithuania, Luxembourg, Poland, Slovenia, and Türkiye, who do not have access to publishing support or sufficient funds.
• Corresponding authors of articles accepted in 2024 based in India, who do not have access to publishing support or sufficient funds to cover the reduced APC applicable.
• Corresponding authors who are currently funded under the EMBO Young Investigator (YIP) or Global Investigator (GIN) schemes.

Please contact [email protected] for additional information.

PRIVACY POLICY

Please see the journal's data privacy policy.